Taiwan’s Aon’s medical family has added new members to the medical display market.
On February 1, 2016, Taiwanese company Anqin Technology announced that it has added a new member to its medical field. The board of directors decided on October 22, 2015 to acquire a 33.3 percent stake in Goomedi Imaging Technology Co., Ltd. (Goomedi Lab.). Formally added a strong new impetus to the An Qin medical family. Founded in 2014, Gemeidi employs 14 people, mainly in R&D and technical personnel. The company has excellent independent R&D and manufacturing capabilities for various special fields of ODM display panels. The medical field has passed cUL/UL and IEC. /EN60601-1 3rd Edition International medical standards.
The global medical display market was US$0.9 billion in 2014, with a projected compound growth rate of 4.5% from 2014 to 2019 (Note). The gross profit margin of medical displays has always been higher than that of consumer displays. Because medical displays have extremely high requirements on resolution, stability and brightness, in addition to producing medical displays, medical devices must be inspected. Registration related regulations. In this respect, Gemeidi has a standard threshold, which cooperates with the ISO 13485 medical quality management standards that Anqin has already passed, and can quickly respond to the needs of international medical manufacturers, and produce mutually beneficial synergies.
At present, Gemeidi's full range of products include 19å‹~55å‹ displays, which can be divided into diagnostic displays, ultrasonic diagnostic displays and surgical displays according to different needs and specifications. The entire product line is fully compatible with DICOM (Digital Imaging and Communications in The Medicine standard, which has a 55-inch surgical display that achieves a UHD 4K x 2K high resolution presentation.
Liu Qinwei, chairman of Anqin Technology, said that since 2006, Anqin has entered the smart medical industry and deepened the field of bedside medical care systems. In recent years, the proportion of medical care has accounted for 24~27% of Anqin's annual revenue. This strategic alliance will be based on the R&D design capabilities of the Gemeidi team, and will be combined with the previous comprehensive medical care system Remedi and the mobile care cart Bytec to expand the original medical map of Avalue to provide customers. More Yuan's product line and integrated services to develop better quality smart medical solutions.
Bempedoic Acid
Bempedoic Acid,Bempedoic Intermediate,Cas 738606-46-7,Cas 123469-92-1
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com